Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…
Global Opioid Induced Constipation (OIC) drug market is estimated to grow at a CAGR of 4.88% during the forecast period of 2017 - 2025. The major drivers responsible for the market growth are:
Rising use of opioid
Increasing geriatric population
Increasing opioid prescription in North America and Europe
Detection of safety threats
Easy availability of improved and effective OIC drugs
Some of the commonly prescribed opioids are Percocet, Vicodin, and codeine.
The global Opioid Induced Constipation (OIC) drug market segments include drug type and prescription type.
Drug types are further classified as follows:
Methyl naltrexone Bromide
Prescription types are further classified as follows:
Over the Counter
Over the counter segment is dominating the market as a doctor's prescription is not required to buy the drugs which make its access easier.
Geographically, the global Opioid Induced Constipation (OIC) is segmented into the following regions:
North America - U.S. & Canada
Asia Pacific - China, Japan, and RoAPAC
Europe - UK, Germany, and RoE
Rest of World - MENA and Latin America
Of these, the North American market is expected to dominate the global OIC drugs market during the forecast period on account of the fact that approximately 50% of the population is suffering from OIC. The countries in this region also have the most developed healthcare systems and medical devices industry in the world. The Federal agencies and private firms are equally supporting the market by providing access to the best medical facilities to the consumers. Growing life style oriented diseases, increase in healthcare spending and technological advancement in cardiology are the factors responsible for the growth of this market.
Product launch is the key strategy adopted by the various market players of global Opioid Induced Constipation (OIC) drug market.The AstraZeneca Pharmaceuticals's Movantik developed a partnership with Nektar Therapeutics in 2014 for the treatment of OIC. Another merger of Salix Pharmaceuticals and Progenics Pharmaceuticals developed Relistor drug that is expected to generate around $150 million by 2020. The other major market players include:
Valeant Pharmaceuticals International